Market News AIOpen the app

Erasca, Inc.: Other Events (ERAS)

TrialRead the original at SEC EDGAR
Good for ERAS

Erasca reported tumor responses and favorable safety results for its experimental drugs, and plans to start a pancreatic cancer Phase 3 trial sooner. The studies are still early, and combination efficacy results are not yet available, but the findings support its outlook.

ERAS · Erasca, Inc.

AI read · Good for ERAS

The AI's read

The early results show tumor responses in pancreatic and lung cancer patients, including people whose cancer had already been treated. Most patients stayed on treatment, and the company reported no treatment stops from side effects at the 32 mg dose. These findings support testing ERAS-0015 in a larger pancreatic cancer trial sooner. ERAS-4001 also showed early activity and may be tested alongside ERAS-0015. The evidence is still from Phase 1 studies, and the ERAS-0015 combinations have not yet reported efficacy data. Even so, the response results and reported safety support a positive reading.

Get alerts for ERAS

Follow Erasca, Inc. (ERAS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ERAS
Free on the App Store and Google Play, or on the web.